Scholarlink

<p>Hypoparathyroidism (HPT) is an endocrine disease characterised by hypocalcaemia. It causes neurological, renal, bone and eye symptoms, impairing quality of life (QoL). Therapy is based on vitamin D and calcium; PTH is used in refractory cases. QoL is assessed by generic (SF-36) or specific (HPES, HPQ-28) questionnaires. The use of these questionnaires can be very useful in clinical practice, although currently not recommended by guidelines. New therapies such as palopegteriparatide improve disease control and patient well-being.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ipoparatiroidismo e qualità di vita

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月22日

查看全文
  • Francesco Arcidiacono,
  • Ignazio Barca,
  • Antonio Prinzi,
  • Francesco Frasca,
  • Pasqualino Malandrino

摘要

Hypoparathyroidism (HPT) is an endocrine disease characterised by hypocalcaemia. It causes neurological, renal, bone and eye symptoms, impairing quality of life (QoL). Therapy is based on vitamin D and calcium; PTH is used in refractory cases. QoL is assessed by generic (SF-36) or specific (HPES, HPQ-28) questionnaires. The use of these questionnaires can be very useful in clinical practice, although currently not recommended by guidelines. New therapies such as palopegteriparatide improve disease control and patient well-being.